+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

OpGen Inc (OPGN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 50 Pages
  • August 2023
  • GlobalData
  • ID: 4267304
OpGen Inc (OPGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

OpGen Inc (OpGen) is a precision medicine company that harnesses molecular diagnostics and informatics to prevent infectious diseases caused by multi-drug resistant organisms (MDROs). OpGen develops products that include AREScloud, ARESd, Unyvero LRT Panels, Unyvero Urinary Tract Infection (UTI) Panel, Unyvero System, SARS-CoV-2 test kit, Acuitas molecular diagnostic and Acuitas Lighthouse informatics. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc Key Recent Developments

  • Aug 03, 2023: OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th
  • Jun 26, 2023: Opgen Subsidiary Ares Genetics Successfully Maintains Key Patent Under Opposition in Europe
  • May 15, 2023: OpGen reports Q1 2023 financial results and provides business update
  • May 08, 2023: OpGen to provide business update and financial results for the first quarter 2023 on May 15th at 4:30 p.m. eastern time

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • OpGen Inc - Key Facts
  • OpGen Inc - Key Employees
  • OpGen Inc - Key Employee Biographies
  • OpGen Inc - Major Products and Services
  • OpGen Inc - History
  • OpGen Inc - Company Statement
  • OpGen Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • OpGen Inc - Business Description
  • Other Break-up: Collaboration
  • Overview
  • Performance
  • Other Break-up: Laboratory Services
  • Overview
  • Performance
  • Other Break-up: Product Sales
  • Overview
  • Performance
  • Geographical Segment: Domestic
  • Performance
  • Geographical Segment: International
  • Performance
  • R&D Overview
  • OpGen Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • OpGen Inc - Strengths
  • OpGen Inc - Weaknesses
  • OpGen Inc - Opportunities
  • OpGen Inc - Threats
  • OpGen Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • OpGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • OpGen Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 03, 2023: OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th
  • Jun 26, 2023: Opgen Subsidiary Ares Genetics Successfully Maintains Key Patent Under Opposition in Europe
  • May 15, 2023: OpGen reports Q1 2023 financial results and provides business update
  • May 08, 2023: OpGen to provide business update and financial results for the first quarter 2023 on May 15th at 4:30 p.m. eastern time
  • Apr 05, 2023: OpGen’s subsidiary Curetis signs expansion of R&D collaboration with FIND
  • Apr 03, 2023: OpGen’s subsidiary curetis meets milestones in collaborative research project with InfectoGnostics
  • Mar 30, 2023: OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
  • Mar 22, 2023: OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
  • Mar 01, 2023: OpGen Subsidiary Ares Genetics Announces its move to new Vienna location and provides update on business growth
  • Jan 26, 2023: OpGen subsidiary Ares Genetics announces granting of key patent in China
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • OpGen Inc, Key Facts
  • OpGen Inc, Key Employees
  • OpGen Inc, Key Employee Biographies
  • OpGen Inc, Major Products and Services
  • OpGen Inc, History
  • OpGen Inc, Subsidiaries
  • OpGen Inc, Key Competitors
  • OpGen Inc, Ratios based on current share price
  • OpGen Inc, Annual Ratios
  • OpGen Inc, Interim Ratios
  • OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • OpGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • OpGen Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • OpGen Inc, Performance Chart (2018 - 2022)
  • OpGen Inc, Ratio Charts
  • OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • OpGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GenMark Diagnostics Inc
  • Becton Dickinson and Co
  • Eurofins Genomics GmbH
  • Cepheid Inc
  • bioMerieux SA
  • Laboratory Corp of America Holdings
  • Accelerate Diagnostics Inc
  • Pathnostics
  • T2 Biosystems Inc
  • Quest Diagnostics Inc
  • GenMark Diagnostics Inc
  • AutoGenomics Inc
  • Cepheid Inc
  • bioMerieux SA
  • Becton Dickinson and Co
  • Laboratory Corp of America Holdings
  • Pathnostics
  • T2 Biosystems Inc
  • ARUP Laboratories
  • Accelerate Diagnostics Inc
  • Quest Diagnostics Inc
  • Eurofins Genomics GmbH